Loading...

Sinopharm Group Co. Ltd.

1099.HKHKSE
Healthcare
Medical - Distribution
HK$18.50
HK$-0.14(-0.75%)

Sinopharm Group Co. Ltd. 1099.HK Peers

See (1099.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Medical - Distribution Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
1099.HKHK$18.50-0.75%56.8B7.44HK$2.47+3.99%
2607.HKHK$11.84+1.20%65.2B9.25HK$1.28N/A
2192.HKHK$14.30-2.59%10.5B30.43HK$0.47+1.96%
1931.HKHK$2.00-9.09%3.2B10.53HK$0.19+3.10%
2289.HKHK$7.05+0.57%761.4M13.06HK$0.54+6.94%
9955.HKHK$1.06+0.95%682M-1.10-HK$0.96N/A
0718.HKHK$0.04-2.78%183.8M-0.25-HK$0.14N/A
0673.HKHK$0.30+7.14%147.5M-3.33-HK$0.09N/A
8372.HKHK$0.12+0.00%95.2M11.90HK$0.01+2.10%
0401.HKHK$0.07-1.35%40.9M-7.30-HK$0.01N/A

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

1099.HK vs 2607.HK Comparison

1099.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1099.HK stands at 56.8B. In comparison, 2607.HK has a market cap of 65.2B. Regarding current trading prices, 1099.HK is priced at HK$18.50, while 2607.HK trades at HK$11.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1099.HK currently has a P/E ratio of 7.44, whereas 2607.HK's P/E ratio is 9.25. In terms of profitability, 1099.HK's ROE is +0.09%, compared to 2607.HK's ROE of +0.06%. Regarding short-term risk, 1099.HK is less volatile compared to 2607.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1099.HK.

Stock Price Comparison

Loading...

Frequently Asked Questions

;